BioCentury
ARTICLE | Clinical News

ProstVac regulatory update

May 10, 2010 7:00 AM UTC

FDA granted Fast Track designation to Bavarian Nordic's ProstVac to treat asymptomatic or minimally symptomatic, metastatic castration-resistant prostate cancer (mCRPC). The company plans to start a P...